There has recently been resurgence in interest for the use of replication-selective (oncolytic)
viruses for the treatment of cancers. This has been fueled by positive clinical data and the …

The vaccinia virus/bacteriophage T7 hybrid transient expression system employs a
recombinant vaccinia virus that encodes the T7 RNA polymerase gene, a plasmid vector …

In cell culture infections with vaccinia virus the number of counted virus particles is
substantially higher than the number of plaques obtained by titration. We found that standard …

Oncolytic viruses are promising cancer therapies due to their selective killing of tumor cells
and ability to stimulate the host immune system. As an oncolytic virus platform, vaccinia virus …

Background The vaccinia virus (VACV) isolates, Guarani P1 virus (GP1V) and Passatempo
virus (PSTV), were isolated during zoonotic outbreaks in Brazil. Each one of them belongs to …

Recombinant vaccinia viruses that express defective retroviral vectors upon a single
infection event in normal host cells were constructed. The gag-pol and envelope genes and …

Vectored vaccines based on highly attenuated modified vaccinia Ankara (MVA) are reported
to be immunogenic, tolerant to pre-existing immunity, and able to accommodate and stably …

Abstract Background Vaccinia virus (VACV)-DUKE was isolated from a lesion on a 54 year
old female who presented to a doctor at the Duke University Medical Center. She was …

Oncolytic or replication-selective viruses have been used as powerful tools for the delivery of
therapeutic genes to tumors. Because these vectors are capable of replicating within the …

The modified vaccinia virus Ankara (MVA) strain is a candidate vector for vaccination against
pathogens and tumors, due to safety concerns and the proven ability of recombinants based …